QID 378425

Date Published: 2023-04-19

QID 378425: Oracle Java Standard Edition (SE) Critical Patch Update - April 2023 (CPUAPR2023)

Oracle Java Runtime Environment (JRE) is a platform that supports the execution of programs that are developed using the Java programming language. The JRE platform also supports Java Applets, which can be loaded from Web pages.

Oracle Java JRE and JDK contain multiple remotely exploitable vulnerabilities that affect various components.

Affected Versions:
Oracle Java SE: 8u371, 8u371-perf, 11.0.18, 17.0.6, 20;

QID Detection Logic (Authenticated):
Operating System: Windows
This QID checks for the file or product version of jvm.dll or wsdetect.dll or verify.dll.

QID Detection Logic (Authenticated):
Operating System: Linux
This QID checks product version from the java binary.

Successful exploitation could allow an attacker to affect the confidentiality, and integrity of data on the target system.

  • CVSS V3 rated as High - 7.4 severity.
  • CVSS V2 rated as High - 7.1 severity.
    • Solution
    The vendor has released updates to resolve these issues.

    Customers are advised to refer to vendor advisory Oracle Critical Patch Update Advisory - April 2023

    Vendor References

    CVEs related to QID 378425

    CVE-2023-21930 | CVE-2023-21967 | CVE-2023-21954 | CVE-2023-21939 | CVE-2023-21938 | CVE-2023-21968 | CVE-2023-21937 |
    Software Advisories
    Advisory ID Software Component Link
    Oracle Critical Patch Update Advisory - April 2023 URL Logo www.oracle.com/security-alerts/cpuapr2023.html
    By selecting these links, you may be leaving CVEreport webspace. We have provided these links to other websites because they may have information that would be of interest to you. No inferences should be drawn on account of other sites being referenced, or not, from this page. There may be other websites that are more appropriate for your purpose. CVEreport does not necessarily endorse the views expressed, or concur with the facts presented on these sites. Further, CVEreport does not endorse any commercial products that may be mentioned on these sites. Please address comments about any linked pages to [email protected].